1. Home /
    2. Altai Protocol Library /
  2. New Indication: Crizotinib for ALK-positive inflammatory myofibroblastic tumor

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Indication: Crizotinib for ALK-positive inflammatory myofibroblastic tumor

New Indication: Crizotinib for ALK-positive inflammatory myofibroblastic tumor
Study:
  • Multicenter, single‐arm, open‐label phase 1b study (PROFILE 1013)
  • ALK‐positive advanced malignancies other NSCLC (N:44)
  • Crizotinib 250 mg x 2 /day
Efficacy:
  • ORR: 53% (95% CI, 28-77), CR:8/18 and PR:1/18 patients for lymphoma
  • ORR: 67% (95% CI, 30-93), CR:8/9 and PR:1/9 patients for IMT
  • 2 year PFS: 63% and 67% (lymphoma and IMT)
Safety:
  • Treatment related AEs: 88.6%
  • Any grade AEs: Diarrhea: 45.5%, vision disorder: 45.5%, nausea:%38.6%
  • Serious AEs:20.5%  CPK increase: 6.8%

Am J Hematol. 2018 May;93(5):607-614.

Gambacorti-Passerini C, Orlov S, Zhang L, et al. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.

https://doi.org/10.1002/ajh.25043

Reviewed by Hasan Çağrı Yıldırım, MD on Aug 16, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More